New Acne Treatment Enters Phase III Clinical Testing
The AURORA trial for denifanstat could offer a new management option for adolescents and adults with moderate to severe acne.
Updated on Oct. 23, 2026 in Beauty
Live Poll
Do you believe new medical clinical trials are effectively addressing unmet needs for common skin conditions?
Sagimet Biosciences has initiated a U.S. Phase III clinical trial for denifanstat, a potential new treatment for moderate to severe acne. The AURORA study aims to enroll 800 patients, including adolescents aged 12 and older, to support a future regulatory filing.
Why it matters
This trial marks a significant step toward assessing a new therapeutic option for the estimated 10 million Americans struggling with moderate to severe acne. The research aims to evaluate if this treatment can address persistent cases that may not respond to current standards of care.
The Phase III AURORA trial is recruiting 800 U.S. participants, including 450 adolescents, to evaluate the efficacy of denifanstat in a large-scale study. While previous research in China suggests potential, the definitive results from this U.S.-based study are currently unknown.
The players
Sagimet Biosciences
A biopharmaceutical company developing fatty acid synthase inhibitors for various metabolic and dermatological conditions.
Ascletis Pharma
A biotechnology company headquartered in Hong Kong that holds exclusive rights to develop and commercialize denifanstat in Greater China.
The details
Denifanstat functions as a fatty acid synthase inhibitor, targeting the biological pathways that contribute to acne development. By inhibiting this enzyme, the drug aims to reduce the sebum production and inflammation that characterize moderate to severe breakouts. The ongoing U.S. study builds upon data from a prior 12-week Phase III trial conducted in China.
Timeline
October 23, 2026: Ascletis announced the first patient dosing in the AURORA trial.
Health Landscape
The development of denifanstat represents a novel shift toward metabolic-based interventions for acne. This approach follows a long history of reliance on antibiotics and topicals, aiming to provide a new alternative for patients whose conditions remain difficult to manage.
This clinical trial is currently in the recruitment phase and is not yet a treatment option for the general public. Those interested in potential participation should consult with a dermatologist to determine if clinical research is a safe and appropriate path for their specific skin health.
The takeaway
The AURORA trial is testing whether a new class of medication can help those with severe acne manage their skin health more effectively. If you are struggling with persistent breakouts, continue working with your physician to monitor which current therapies provide the most relief.
Further reading
For more on evolving skin care research and treatment trends, explore our Beauty section.
Live Poll
Do you believe new medical clinical trials are effectively addressing unmet needs for common skin conditions?
